The U.S. FDA commissioner Marty Makary recently said the FDA will be taking action against companies producing “illegal copycat drugs” claiming to be similar to FDA-approved products, Carlos Mendez and Chris Thomas of Reuters reports. Hims and Hers Health (HIMS) stock, the maker of a cheaper $49 version of Novo Nordisk’s (NVO) Wegovy, has plunged since these comments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Why Hims & Hers (HIMS) Stock Is Falling despite the $49 Weight-Loss Pill Buzz
- Eli Lilly Stock (LLY) Falls on News Hims & Hers Is Selling a $49 Weight-Loss Pill
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Novo Nordisk issues statement on ‘inauthentic’ Hims & Hers semaglutide pill
- Hims & Hers Health Stock Rallies on Wegovy Copycat Launch